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Abstract
The aim of our study was to elucidate the role of Rap2B in the development of human suprarenal 
epithelioma and to investigate the effect of Rap2B on suprarenal epithelioma cells migration and 
invasion. We use tissue microarray and immunohistochemistry to evaluate Rap2B staining in 75 
suprarenal epithelioma tissues and 75 tumor-adjacent normal renal tissues. And the expression of 
Rap2B protein in human suprarenal epithelioma cells and tissues was detected by western blot 
simultaneously. The role of Rap2B in suprarenal epithelioma cells migration and invasion was 
detected by using wound healing assay, cell migration assay, and matrigel invasion assay. After 
that, we performed western blot analysis and gelatin zymography to detect MMP-2 protein 
expression and enzyme activity. Our research showed that Rap2B expression was increased in 
tumor tissues compared with tumor-adjacent normal renal tissues. But no correlation was found 
between Rap2B expression and clinicopathological parameters. In addition, we found that Rap2B 
promoted the cell migration and invasion abilities, and Rap2B increased MMP-2 expression and 
enzyme activity in suprarenal epithelioma cells. Our data indicated that Rap2B expression is 
significantly increased in human suprarenal epithelioma and Rap2B can promote the cell 
migration and invasion abilities, which may provide a new target for the treatment of suprarenal 
epithelioma.
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Introduction
Renal cell carcinoma (RCC) represents approximately 90 % of all renal neoplasms and 
accounts for close to 3~5 % of adult overall malignancies [1]; 85 % of RCC is suprarenal 
epithelioma. At the time of initial diagnosis, about 20~25 % of patients have a local 
extension or metastasis, and almost 33 % of patients still develop disease recurrence even 
though they were given curative treatment [2]. Unfortunately, metastatic renal cell 
carcinoma, with widely chemo- and radio-resistance, is a poor response to immunotherapy, 
so current treatments are not effective for this tumor [3]. Improvements in screening and 
advances in treatments have decreased renal cell carcinoma mortality in recent years, but 
renal cell carcinoma, often behaving aggressively, is associated with a poor prognosis [4]. 
Thus, there is an urgent need to develop novel treatments for renal cell carcinoma, especially 
advanced renal cell carcinoma patients.
Rap2B, involved in the Rap2 subfamily, was first discovered when a platelet cDNA library 
was screened by researchers in 1990 [5, 6]. Rap2B belonged to Ras family members whose 
expression can be found increasedly in a variety of human tumors. Furthermore, increasing 
amounts of evidence strongly illustrated the association of the function of Rap2B with 
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tumor. For example, Rap2B participate the pro-survival program conducted by p53 as a new 
player and raise the possibility that targeting Rap2B could sensitize tumor cells to apoptosis 
in response to DNA damage [7]. Rap2B can interact with and activate PLC-ε which was a 
key enzyme located in the plasma membrane and extremely broad distribution, and played 
an important role in promoting bladder transitional cancer cell proliferation and the activity 
could be controlled by small GTPases of the Ras and Rho families [8–13]. These studies 
suggest a meaningful role for Rap2B in the tumorigenesis of human cancers. However, less 
is known about the expression and function of Rap2B in RCC.
In the present study, our data demonstrated that expression of Rap2B was increased in 
suprarenal epithelioma compared with tumor-adjacent normal renal tissue, while was also 
increased in suprarenal epithelioma Caki-1 and 786O cell lines. Based on these reports, we 
speculate that Rap2B also plays an important role in renal cell carcinoma. Soon afterwards, 
we used a tissue microarray (TMA) of human suprarenal epithelioma patients and 
immunohistochemistry to evaluate the expression of Rap2B in relation to clinicopathologic 
features. In addition, we found that Rap2B dramatically increased cell migration and 
invasion abilities by upregulating MMP-2 expression and enzyme activity, which may 
provide a new target for human renal cancer treatment.
Experimental procedures
Patients and samples
The suprarenal epithelioma TMA was purchased from Shanghai Xinchao Biotechnology 
(Shanghai, China). The array dot diameter was 1.5 mm, and each dot represented a tissue 
spot from one individual specimen. Fifty-seven WHO-I, 57 WHO-II, 18 WHO-III, and 18 
WHO-IV were selected and pathologically confirmed. At the same time, it includes 75 cases 
of tumor-adjacent normal renal tissue. In addition, four RCC tissues and paired non-
cancerous tissues were obtained from the affiliated hospital of Xuzhou Medical College.
Cell line and culture conditions
All the cell lines were purchased from the Chinese Academy of Science (Shanghai, China). 
H-K2 and HEK293 were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 15 % fetal calf serum (FCS) at 37 °C in 5 % CO2 using a humidified 
incubator. While human 786O and Caki-1 renal carcinoma cells supplemented with 15 % 
superior placental bovine serum at 37 °C in a humidified atmosphere with 5 % CO2 and 
maintained in RPMI-1640 medium (Thermo) and McCoy’s 5A Medium, respectively.
Immunohistochemistry of TMA
We performed immunohistochemistry according to the avidin-biotinylated HRP complex 
(ABC) method by using a standard ABC kit (Zhongshan biotech, Beijing, China). TMA 
slides was incubated with monoclonal Rabbit anti-Rap2B antibody (1:500) (Abcam, 
Cambridge, USA) overnight at 4 °C, while diaminobenzidine (DAB; Zhongshan Biotech, 
Beijing, China) was used to produce a brown precipitate. Then, a biotinylated secondary 
antibody (Zhongshan Biotech, Beijing, China) was incubated in the sections at room 
temperature for 30 min. The sections were followed by the incubation with streptavidin-
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peroxidase (Zhongshan Biotech, Beijing, China) for an additional 30 min. After rinsing with 
PBS three times for 5 min, the sections were stained using DAB (Zhongshan Biotech, 
Beijing, China) for 15 min, rinsed in distilled water, and counterstained with hematoxylin. 
The immunoreactivity was assessed blindly by two qualified pathologists using light 
microscopy (Olympus BX-51 light microscope), and the image was collected by Camedia 
Master C-3040 digital camera. The expression of Rap2B was graded as positive when >5 % 
of tumor cells showed immunopositivity. Biopsies with <5 % tumor cells showing 
immunostaining were considered negative.
Transfection
The pDNA3-control and pDNA3-Rap2B expression plasmids were gifts from Dr. Yan-Ping 
Zhang (The University of North Carolina at Chapel Hill, NC, USA). Transfection of the 
plasmids into the 786O cells was carried out using Lipofectamine 2000 transfection reagent 
(Invitrogen, Shanghai, China) following the manufacturer’s protocol. Twenty-four hours 
after transfection, cells were harvested to do wound healing assay, cell migration and 
invasion assay. Transfection of small-interfering RNA (siRNAs) was carried out using 
siLentFect Lipid Reagent (Bio-Rad, Hercules, CA, USA) according to the manufacturer’s 
instructions. Then, cells were subjected and assayed 48 h after transfection.
Wound-healing assay and transwell assay
The supernatant of cell was collected after transfection with plasmid or siRNA, in which 
786O cells were cultured. Meanwhile, a scratch was drawn in the center of the well. The 
distance between the cells bordering the scratch was measured every 6 h within 12 h. 
Transwell, pre-coating at 37 °C for 3 h, was incubated in serum-free MEM/EBSS for 30 
min. 786O cells were harvested, and then seeded in serum-free medium at a density of 
4×104 cells/ml. Altogether, 100 μl of the cell suspension was put onto the upper layer of 
transwell. After coating 12 or 24 h, the cells were fixed by formalin and stained by trypan 
blue and counted.
Western blot analysis
To determine Rap2B protein levels by western blot, cells were transiently transfected with 
plasmids for 24 h. Then, cells were harvested and washed twice with PBS. After cell lysis, 
the protein concentration was determined by using the bicinchoninic acid (BCA) assay. 
Proteins were separated by SDS-PAGE and then electrotransfer onto nitrocellulose 
membranes. The primary antibodies were utilized for western blot: rabbit anti-Rap2B 
(Abcam, Cambridge, MA, USA), rabbit anti-MMP-2 (Cell Signaling Technology, Beverly, 
MA, USA) and mouse anti-β-actin (Boster Biotechnology, Wuhan, China). The membranes 
were then washed and incubated with alkaline phosphatase conjugated secondary antibodies 
(Cell Signaling Technology, Beverly, MA, USA) for 2 h at room temperature. Detection was 
performed by an enhanced chemiluminescence method.
Gelatin zymography analysis
Gelatinase activity was determined by gelatin zymography according to the method 
previously described. Cells were incubated in RPMI-1640 without serum overnight after 24 
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h of transfection in a 60-mm culture dish. After overnight, culture conditioned medium was 
obtained with Ultracel 30-k centrifugal filters (Millipore, Billerica, MA) at 5,000×g for 20 
min at 4 °C to measure the gelatinase activity. After concentrating, 25-μg proteins was 
loaded in non-redenaturing conditions on a 10 % polyacrylamide gel containing 0.1 % 
gelatin in order to electrophoresis. Then, the gel following rinsing with 2.5 % Triton X-100 
for 1 h at room temperature was followed by incubation buffer (20-mM Tris–HCl, pH 8.0, 
150-mM NaCl, 5-mM CaCl2, and 0.01 % NaN3) overnight at 37 °C, stained with 0.5 % 
Coomassie blue R250 (Sigma) for 1 h, and destained with 30 % methanol and 10 % glacial 
acetic acid until depicting MMPs as clear white bands appeared on the blue background.
Calculations and statistical analysis
Data expressed in figures or given in the text are the means± SD from >3 independent 
experiments. The differences significance of TMA was assessed using the SPSS 16.0 
software (SPSS). X2 test was used to evaluate the association between staining of Rap2B 
and the clinicopathologic parameters of the suprarenal epithelioma patients, including age, 
gender, WHO grade, and histologic type. Statistical analysis in treatment groups were 
assessed by two-factor analysis of variance procedures and the Dunnett’s t test. A value was 
regarded statistically significant when P<0.05.
Results
The expression of Rap2B is increased in suprarenal epithelioma
To determine whether there is a different expression of Rap2B between normal renal cells 
and carcinoma cells, we performed western blot to measure the Rap2B expression in normal 
renal cells and different carcinoma cells. Our results showed that the level of Rap2B 
expression is drastically increased in human 786O and Caki-1 renal carcinoma cells, 
compared with H-K2 and HEK293 normal renal cells (Fig. 1a).
To further study the expression of Rap2B in suprarenal epithelioma, we performed to 
investigate the expression of Rap2B protein between tumor-adjacent normal renal tissue and 
four suprarenal epithelioma patients’ tissue. These results are consistent with the previous 
cell study, a significant difference in Rap2B staining was observed between tumor-adjacent 
normal renal tissue and malignant tumor (Fig. 1b). And Fig. 2 presented that positive Rap2B 
staining was recorded in 84.5 and 4.9 % of the biopsies in tumor-adjacent normal renal 
tissue and malignant tumor in TMA, respectively. Figure 2 also displayed that Rap2B mainly 
located at the membrane suprarenal epithelioma patients.
Association between the expression of Rap2B and clinicopathological parameters
There is the association between the suprarenal epithelioma prognosis and 
clinicopathological parameters. We assessed the correlation between the expression of 
Rap2B and the clinicopathological data, including WHO grade and histologic type. We did 
not find significant correlations between the expression level of Rap2B and biological 
factors such as patients’ age (P=0.591), gender (P=0.315), and WHO grade (P=0.575). As 
we all know, WHO grade and histologic type are important prognostic markers for the 
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patients with suprarenal epithelioma. But significant correlations were not found between 
Rap2B expression and these markers (Table 1).
Over-expression of Rap2B could promote cell motility in human 786-O renal carcinoma cell 
line in vitro
Since the expression of Rap2B is notably increased in suprarenal epithelioma tissue, we 
detected the further involvement of Rap2B in the migration and invasion of human 786O 
renal carcinoma cell. We transiently transfected 786O cells with pDNA3-control and 
pDNA3-Rap2B plasmids, Rap2B protein was significantly over-expressed in cancer cell 
(Fig. 3a). And Rap2B protein expression decreased in cancer cells after knockdown Rap2B 
(Fig. 4a). In cell wound-healing assay, we found that the healing speed of the scratch in 
786O cells cultured with supernatant from 786O/Rap2B was higher than that in 786O cells 
cultured with supernatant from 786O/pDNA3 (P<0.05) (Fig. 3b). Similarly, the migration 
and invasion results corroborated the wound-healing assay. Our data revealed that 786O cell 
cultured in supernatant from 786O/Rap2B migrated and invaded faster than 786O cells 
cultured in supernatant from 786O/pDNA3 (P<0.05) (Fig. 3c, d), while knockdown Rap2B 
inhibited the suprarenal epithelioma cell growth and motility (Fig. 4b–d). Those findings 
illustrated that Rap2B could promote the migration and invasion of 786O cell in vitro.
Over-expression of Rap2B promoted MMP-2 expression and activity in 786-O cells in vitro
We next investigated the mechanism by which Rap2B promoted the migration and invasion 
of 786O cells. In cancer cells, the invasive ability can be regulated by MMPs [14]. Western 
blot and gelatin zymography was performed to measure the MMPs expressions and ability, 
respectively, in 786O cells. Figure 5a illustrated that the MMP-2 protein level were 
dramatically increased in 786O-Rap2B cells. And the MMP-2 protein level dramatically 
decreased in 786O-siRap2B cells compared with the control cells in Fig. 5b. In addition, 
further result showed the MMP-2 activity was significantly increased after transfecting an 
expression plasmid for Rap2B in 786O cells when compared with control cells (Fig. 5c, d).
Discussion
Rap2B gene was initially cloned from the complementary DNA (cDNA) library of human 
platelet by Ohmstede in 1990 [5]. Rap2B gene is located at 3q25.2 of human chromosome 
which is the hot area of cancer research, and its cDNA contains an open reading frame of 
552 bp. Though Rap2B contains conserved domain and belongs to the Ras superfamily, and 
previous studies pointed out that Rap2B have a relationship with the occurrence and 
development of some tumors, including lung cancer, but little is known about the expression 
and role of Rap2B in renal carcinoma. In this work, our findings demonstrated that Rap2B 
expression is significantly increased in renal carcinoma compared with tumor-adjacent 
normal renal tissue by TMA technique (Fig. 2). And consistent with the above findings, the 
expression also highly increased in suprarenal epithelioma cell and tissue with relatively 
lower levels seen in the normal renal cell and tissue by Western blot (Fig. 1a, b). This 
observation implied that Rap2B might play some potential role in the development and 
progression of renal carcinoma. We further carried out experimental studies on the function 
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of Rap2B. In the function study, we first test the effects of Rap2B on the motility of 786O 
cells by wound-healing and migration analysis.
In wound-healing assay, Rap2B could accelerate growth rate of 786O cells (Fig. 3b). But 
what will take occurrence if Rap2B was knocked down? RNA interference (RNAi) and 
small-interfering RNA molecule (siRNA) corresponding to any endogenous gene of interest, 
can be used as a mechanism of post-transcriptional gene silencing to result in the mRNA 
degradation of the targeted gene [15, 16]. Therefore, we referred siRNA as an extremely 
powerful method for assessing and eliminating Rap2b gene function. After inhibiting the 
expression of Rap2B in vitro assay (Fig. 4a), Fig. 4b exhibited that knockdown of Rap2B in 
human suprarenal epithelioma cell lines reduced the movement. And the results are in 
agreement with that Rap2B staining also played important role in migration of human 
suprarenal epithelioma cell lines (Figs. 3c and 4c).
Previous reports have suggested that Rap2B, encoding 183 amino acids, is a Ras-related low 
molecular weight GTP-binding protein. Rap proteins are widely expressed, but the 
expression and location of isoforms still have the tissue-specific. The function of Rap2B in 
cancers may also have tissue/cell-type specificity. We reviewed that Rap2B located at the 
membrane in TMA (Fig. 2) similar to Torti and Lapetina’s research [17]. Simultaneously, 
the above findings implied that some secreted proteins did participate in Rap2B inhibiting 
effect on the migration of 786O cells.
In order to verify the migration and invasion ability after transfecting Rap2B plasmid, 
proliferation-associated proteins are commonly used. Matrix metalloproteinases (MMPs) are 
a family of zinc-dependent endopeptidase that are capable of degrading components of the 
basement membrane and the extracellular matrix (ECM), allowing cancer cells’ ability of 
migration and invasion [18, 19]. Moreover, cell migration was associated with high level of 
MMP-2 [20] and increasing expression of MMP-2 is associated with enhanced tumor 
invasion and metastasis [21]. In this study, we also found that Rap2B promoted suprarenal 
epithelioma cells motility by regulating the MMP-2 protein expression (Fig. 5a) and 
knockdown of Rap2B in suprarenal epithelioma cells resulted in significantly inhibiting cell 
abilities of migration and invasion (Fig. 5b). Our further data showed that the MMP-2 
enzyme activity could be up-regulated after Rap2B over-expression in suprarenal 
epithelioma cell (Fig. 5c, d). However, it remains to be elucidated how Rap2B regulates 
MMP-2 expression and activity. Previous reports have shown that PI3K/Akt and MAPK 
signaling pathway, NF-κB activation and transcription factor Sp1 is involved in the 
regulation of MMP-2 expression and activation [22–24]. Our further study in the future will 
try to find the exact mechanism underlying the MMP-2 regulation by Rap2B.
In conclusion, our study shows that the expression of Rap2B is significantly increased in 
human suprarenal epithelioma. Strikingly, our data indicate that over-expression of Rap2B 
may promote suprarenal epithelioma cell migration through increasing MMP-2 protein 
expression and ability. The clear molecular mechanisms of how Rap2B regulates suprarenal 
epithelioma cell migration and invasion still need further investigation, but the findings 
regarding Rap2B provide evidences for the contribution of developments to human 
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suprarenal epithelioma. Taken together, our data strongly suggest that Rap2B might be 
considered as a novel therapeutic target for suprarenal epithelioma.
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Fig. 1. 
Rap2B protein expression in suprarenal epithelioma cells and tissues. a In contrast to normal 
renal cells, the Rap2B expression is increased in 786-O cell lines. b Whole-cell protein 
extracts were further prepared from four paired tumor-adjacent normal renal tissues (N) and 
RCC tissues (T). The Rap2B protein level was determined by Western blot analysis
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Fig. 2. 
Correlation between Rap2B expression and suprarenal epithelioma progression is shown. a 
Significant difference in Rap2B staining was observed between malignant tumor (MT) and 
tumor-adjacent normal renal tissue (AT). b The distribution of the difference in Rap2B 
staining (P<0.05, X2 test). Magnification ×400
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Fig. 3. 
Overexpression of Rap2B promotes the cell motility in suprarenal epithelioma cells. a 
Twenty-four hours after transfection, the expression of Rap2B was evaluated by Western 
blot in 786O cell and quantitative analysis shows that Rap2B protein was over-expressed 
after transfection. Actin was used as an internal control. b Wound-healing assay was 
executed that over-expression Rap2B promoted proliferation ability in wound closure 
compared with pcDNA3-control transfected group; c, d Cell migration assay and Matrigel 
cell invasion assay were performed after Rap2B over-expression in 786O cells. Rap2B over-
expression promoted the ability to migrate and invade through Boy-den chamber. All 
experiments were carried out in triplicate. Data are shown as mean±SE. (EB, endogenous 
band) *P<0.05, **P<0.01, ***P<0.001
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Fig. 4. 
Knockdown Rap2B inhibits the suprarenal epithelioma cells motility. a Forty-eight hours 
after transfection, the expression of Rap2B was evaluated by western blot in 786O cell and 
quantitative analysis shows that Rap2B protein was decreased after Rap2B knockdown. 
Actin was used as an internal control. b Wound-healing assay was executed after Rap2B 
knockdown in 786O cells. There was a significant delay in wound closure compared with 
pDNA3-control transfected group. c, d Cell migration assay and matrigel cell invasion assay 
were performed after Rap2B knockdown in 786O cells. The knockdown of Rap2B decreased 
the ability to migrate and invade through Boy-den chamber. All experiments were carried 
out in triplicate. Data are shown as mean±SE. *P<0.05, ***P<0.001
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Fig. 5. 
Rap2B increases MMP-2 expression and ability in 786O cell. a Western blot analysis 
showed that MMP-2 expression was increased in suprarenal epithelioma cells after 
transfection of Rap2B. b In siRap2B and control group for 786O cell lines, the MMP-2 
protein level was dramatically decreased in 786O-siRap2B cells. c, d Gelatin zymography 
confirmed that Rap2B over-expression can increase the MMP-2 ability compared to control. 
All experiments were carried out in triplicate. ***P<0.01
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Table 1
Rap2B staining and clinicopathological characteristics of 75 suprarenal epithelioma patients
Variables Rap2B staining
Negative, no. (%) Positive, no. (%) Total P*
Age (years)
 <57 9 (21.4) 33 (78.6) 42 0.591
 ≥57 7 (21.9) 25 (78.1) 32
Gender
 Male 12 (24.0) 38 (76.0) 50 0.315
 Female 4 (16.0) 21 (84.0) 25
WHO grade
 Benign (I–II) 12 (21.4) 45 (78.9) 57 0.575
 Malignant (III–IV) 4 (22.2) 14 (77.8) 18
*
χ2 test
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